David Amsellem Analyst PerformanceSenior Research Analyst at Piper SandlerDavid Amsellem is a stock analyst at Piper Sandler in the healthcare sector, covering 29 publicly traded companies. Over the past year, David Amsellem has issued 60 stock ratings, including strong buy, buy, and hold recommendations. While full access to David Amsellem's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Amsellem's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings199 Last 11 YearsBuy Recommendations74.24% 147 Buy RatingsCompanies Covered29 Unique Companies Ratings Distribution198RatingsDistribution of strong buy, buy, hold, and sell ratings by David Amsellem.RatingPercentageCount Strong Buy1.5%3 ratings Buy72.7%144 ratings Hold17.7%35 ratings Sell8.1%16 ratingsOut of 198 total stock ratings issued by David Amsellem at Piper Sandler, the majority (72.7%) have been Buy recommendations, followed by 17.7% Hold, 8.1% Sell, and 1.5% Strong Buy.Best & Worst CallsBest Call0000.0%INDVMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%AVDLMay 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ79.3% of companies on NASDAQ23 companiesNYSE17.2% of companies on NYSE5 companiesNYSEAMERICAN3.4% of companies on NYSEAMERICAN1 companyDavid Amsellem, an analyst at Piper Sandler, currently covers 29 companies listed on NASDAQ, NYSE and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare29 companies100.0%David Amsellem of Piper Sandler specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS25 companies86.2%BIOTECHNOLOGY4 companies13.8% About David AmsellemDavid Amsellem is a managing director and senior research analyst at Piper Sandler covering biotechnology. Amsellem has more than 20 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006. Amsellem earned a Bachelor of Science degree from Cornell University.Follow on LinkedIn David Amsellem's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAXSMAxsome Therapeutics9/18/2026Reiterated Rating$210.11$258.00Overweight$0.0000.00% ROIBMYBristol Myers Squibb9/16/2026Reiterated Rating$63.69$82.00Overweight$0.0000.00% ROIVTRSViatris9/16/2026Boost Price Target$16.65$13.00Neutral$0.0000.00% ROIBIIBBiogen9/3/2026Reiterated Rating$222.67$245.00Overweight$0.0000.00% ROIABBVAbbVie8/20/2026Boost Price Target$265.63$303.00Overweight$0.0000.00% ROIAMGNAmgen8/20/2026Boost Price Target$442.36$457.00Overweight$0.0000.00% ROIAMPHAmphastar Pharmaceuticals8/7/2026Lower Price Target$21.26$20.00Neutral$0.0000.00% ROIDFTXDefinium Therapeutics8/7/2026Reiterated Rating$45.22$75.00Overweight$0.0000.00% ROICOLLCollegium Pharmaceutical8/7/2026Reiterated Rating$28.91$43.00Neutral$0.0000.00% ROIJAZZJazz Pharmaceuticals8/4/2026Boost Price Target$251.58$310.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. NBIXNeurocrine Biosciences7/31/2026Boost Price Target$166.71$210.00Overweight$0.0000.00% ROICORTCorcept Therapeutics7/30/2026Reiterated Rating$117.99$165.00Overweight$0.0000.00% ROIALKSAlkermes7/28/2026Reiterated Rating$52.73$65.00Overweight$0.0000.00% ROITEVATeva Pharmaceutical Industries7/28/2026Boost Price Target$31.22$44.00Overweight$0.0000.00% ROIDFTXDefinium Therapeutics7/24/2026Reiterated Rating$42.93$73.00Overweight$0.0000.00% ROIBIIBBiogen7/14/2026Reiterated Rating$194.27Overweight$0.0000.00% ROIABBVAbbVie6/23/2026Reiterated Rating$234.02$298.00Overweight$0.0000.00% ROIAMGNAmgen6/12/2026Reiterated Rating$354.39Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals5/22/2026Boost Price Target$239.40$301.00Overweight$0.0000.00% ROIBIIBBiogen5/15/2026Reiterated Rating$191.37$225.00Overweight$0.0000.00% ROIAMGNAmgen5/14/2026Lower Price Target$336.64$427.00Overweight$0.0000.00% ROIABBVAbbVie5/14/2026Boost Price Target$208.39$298.00Overweight$0.0000.00% ROIAMPHAmphastar Pharmaceuticals5/11/2026Reiterated Rating$18.89$21.00Neutral$0.0000.00% ROIDFTXDefinium Therapeutics5/8/2026Reiterated Rating$23.20$48.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences5/6/2026Boost Price Target$144.75$207.00Overweight$0.0000.00% ROICORTCorcept Therapeutics5/1/2026Boost Price Target$46.52$88.00Overweight$0.0000.00% ROITEVATeva Pharmaceutical Industries4/30/2026Reiterated Rating$35.03$42.00Overweight$0.0000.00% ROIOGNOrganon & Co.4/28/2026Upgrade$13.16$14.00Neutral$0.0000.00% ROIABBVAbbVie4/23/2026Lower Price Target$200.43$294.00Overweight$0.0000.00% ROIBIIBBiogen4/14/2026Upgrade$176.37$214.00Overweight$0.0000.00% ROIDFTXDefinium Therapeutics4/10/2026Initiated Coverage$21.42$49.00Overweight$0.0000.00% ROIDFTXDefinium Therapeutics4/9/2026Upgrade$21.93Strong-Buy$0.0000.00% ROIALKSAlkermes3/24/2026Lower Price Target$27.71$43.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals3/19/2026Boost Price Target$180.89$232.00Overweight$0.0000.00% ROITEVATeva Pharmaceutical Industries3/4/2026Reiterated Rating$32.31$41.00Overweight$0.0000.00% ROIPTHSPelthos Therapeutics2/27/2026Initiated Coverage$23.00$48.00Overweight$0.0000.00% ROIBMYBristol Myers Squibb2/23/2026Reiterated Rating$60.66$75.00Overweight$0.0000.00% ROIAMGNAmgen2/18/2026Boost Price Target$373.36$432.00Overweight$0.0000.00% ROIABBVAbbVie2/18/2026Boost Price Target$232.69$299.00Overweight$0.0000.00% ROIBIIBBiogen2/9/2026Boost Price Target$201.18$177.00Neutral$0.0000.00% ROIIran War WARNING: Something Just Changed (Ad)A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.Click here to see what the source revealed behind closed doors.VTRSViatris1/28/2026Boost Price Target$13.12$12.00Neutral$0.0000.00% ROIBMYBristol Myers Squibb1/28/2026Reiterated Rating$55.58$66.00Overweight$0.0000.00% ROIAXSMAxsome Therapeutics1/16/2026Boost Price Target$174.14$223.00Overweight$0.0000.00% ROIFENCAdherex Technologies1/9/2026Initiated Coverage$7.58$18.00Overweight$0.0000.00% ROITEVATeva Pharmaceutical Industries12/22/2025Boost Price Target$30.39$40.00Overweight$0.0000.00% ROIJAZZJazz Pharmaceuticals12/10/2025Reiterated Rating$162.26$219.00Overweight$0.0000.00% ROIESPREsperion Therapeutics11/25/2025Initiated Coverage$3.17$9.00Overweight$0.0000.00% ROIESPREsperion Therapeutics11/24/2025Upgrade$3.69Strong-Buy$0.0000.00% ROIBIIBBiogen11/21/2025Reiterated Rating$168.18$157.00Neutral$0.0000.00% ROIAMGNAmgen11/14/2025Boost Price Target$336.00$381.00Overweight$0.0000.00% ROIAQSTAquestive Therapeutics11/7/2025Boost Price Target$6.13$8.00Overweight$0.0000.00% ROIXERSXeris Biopharma11/7/2025Boost Price Target$7.44$8.00Neutral$0.0000.00% ROIAMGNAmgen11/5/2025Reiterated Rating$315.24Overweight$0.0000.00% ROIABBVAbbVie11/5/2025Reiterated Rating$213.49$289.00Overweight$0.0000.00% ROIINDVIndivior10/31/2025Reiterated Rating$29.08$41.00Overweight$0.0000.00% ROIAMRXAmneal Pharmaceuticals10/31/2025Reiterated Rating$10.93$13.00Overweight$0.0000.00% ROINBIXNeurocrine Biosciences10/29/2025Boost Price Target$139.15$179.00Overweight$0.0000.00% ROIALKSAlkermes10/23/2025Reiterated Rating$31.09$45.00Overweight$0.0000.00% ROIABBVAbbVie10/10/2025Boost Price Target$231.03$284.00Overweight$0.0000.00% ROISUPNSupernus Pharmaceuticals10/9/2025Upgrade$48.00$65.00Overweight$0.0000.00% ROIBIIBBiogen9/12/2025Boost Price Target$143.71$118.00Neutral$000.0000.00% ROISUPNSupernus Pharmaceuticals8/29/2025Boost Price Target$45.26$40.00Neutral$00.0000.00% ROIAMGNAmgen8/25/2025Boost Price Target$289.76$342.00Overweight$000.0000.00% ROIBIIBBiogen8/14/2025Boost Price Target$133.65$118.00Neutral$000.0000.00% ROIABBVAbbVie8/12/2025Initiated Coverage$198.46$231.00Overweight$000.0000.00% ROIABBVAbbVie8/11/2025Upgrade$204.78Strong-Buy$000.0000.00% ROIANIPANI Pharmaceuticals8/8/2025Reiterated Rating$81.68$94.00Overweight$00.0000.00% ROIAMPHAmphastar Pharmaceuticals8/8/2025Lower Price Target$21.62$25.00Neutral$00.0000.00% ROICORTCorcept Therapeutics8/1/2025Lower Price Target$67.17$121.00Overweight$000.0000.00% ROINBIXNeurocrine Biosciences7/31/2025Boost Price Target$132.66$175.00Overweight$000.0000.00% ROIAMGNAmgen6/27/2025Reiterated Rating$280.30$328.00Overweight$000.0000.00% ROIBIIBBiogen6/12/2025Reiterated Rating$132.02$115.00Neutral$000.0000.00% ROIAMGNAmgen5/16/2025Lower Price Target$271.02$328.00Overweight$000.0000.00% ROIOGNOrganon & Co.5/15/2025Lower Price Target$8.75$18.00Overweight$00.0000.00% ROICOLLCollegium Pharmaceutical5/9/2025Reiterated Rating$28.47$37.00Neutral$00.0000.00% ROIJAZZJazz Pharmaceuticals5/7/2025Reiterated Rating$104.84$147.00Overweight$000.0000.00% ROINBIXNeurocrine Biosciences5/6/2025Reiterated Rating$120.29$154.00Overweight$000.0000.00% ROIBMYBristol Myers Squibb4/22/2025Initiated Coverage$48.95$65.00Overweight$00.0000.00% ROICORTCorcept Therapeutics4/3/2025Boost Price Target$83.81$131.00Overweight$00.0000.00% ROIAMPHAmphastar Pharmaceuticals3/21/2025Lower Price Target$27.94$32.00Neutral$00.0000.00% ROIXERSXeris Biopharma3/7/2025Reiterated Rating$4.36$4.00Neutral$0.0000.00% ROIINDVIndivior3/6/2025Lower Price Target$10.01$13.00Overweight$00.0000.00% ROIVTRSViatris3/5/2025Reiterated Rating$9.60$10.00Neutral$00.0000.00% ROICORTCorcept Therapeutics2/27/2025Boost Price Target$63.37$78.00Overweight$00.0000.00% ROIJAZZJazz Pharmaceuticals2/26/2025Reiterated Rating$147.16$176.00Overweight$000.0000.00% ROIAMGNAmgen2/10/2025Boost Price Target$293.54$329.00Overweight$000.0000.00% ROIAMPHAmphastar Pharmaceuticals2/4/2025Downgrade$33.39$36.00Neutral$00.0000.00% ROICOLLCollegium Pharmaceutical2/4/2025Lower Price Target$31.20$36.00Neutral$00.0000.00% ROITEVATeva Pharmaceutical Industries1/17/2025Boost Price Target$21.68$30.00Overweight$00.0000.00% ROIAVDLAvadel Pharmaceuticals1/10/2025Lower Price Target$7.70$13.00Overweight$00.0000.00% ROIMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (Ad)In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.See Jim Rickards' full market warning and what it means for your portfolio Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank Aktiengesellschaft Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
